Print ISSN: 2395-1443
Online ISSN: 2395-1451
CODEN : IJCEKF
Indian Journal of Clinical and Experimental Ophthalmology (IJCEO) is open access, a peer-reviewed medical journal, published quarterly, online, and in print, by the Innovative Education and Scientific Research Foundation (IESRF) since 2015. To fulfil our aim of rapid dissemination of knowledge, we publish articles ‘Ahead of Print’ on acceptance. In addition, the journal allows free access (Open Access) to its content, which is likely to attract more readers and citations of articles published in IJCEO. Manuscripts must be prepared in more...Null
Author Details :
Volume : 5, Issue : 1, Year : 2019
Article Page : 108-113
https://doi.org/10.18231/2395-1451.2019.0024
Abstract
Purpose: A retrospective study conducted to evaluate the profile of patients with conjunctival and epibulbar lesions who underwent surgical excision with or without ocular surface reconstruction.
Setting: This study included 126 patients of either sex diagnosed to have benign and malignant tumors of conjunctiva, eyelid and orbit who were subjected to excision biopsy.
Materials and Methods: A retrospective chart review of all patients treated between 2009 to 2015 was done. Only those patients whose clinical diagnosis was confirmed by histopathology examination were included.
Results: Of the 126 patients 66(552.38%) were males and 60(47.62%) were females with mean age 40.77 years (1-80years). In a total 126 patients conjunctival tumors were found in 46(36.50%), lid lesions in 53(42.06%) and orbital lesions in 27(21.42%).
Keywords: Conjunctival lesions, Epibulbar lesions.
How to cite : Banakar R, Muddebihal S, Clinicopathological study of conjunctival and epibulbar lesions. Indian J Clin Exp Ophthalmol 2019;5(1):108-113
This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.